glp 1 super responders Researchers move closer to matching patients with GLP-1 drug that works best for them Decoding the hallmarks of GLP-1RA

Description

GLP-1 receptor agonists used for the treatment of diabetes, have shown some neuroprotective effects in cellular and animal models of Alzheimers disease (AD) and Parkinsons disease (PD)

The Protein-Muscle Problem Research shows that up to 20 to 25 percent of weight lost on GLP-1 medications can come from muscle rather than fat

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been pivotal for obesity treatment, achieving 1525 % weight loss over 1224 months, but questions remain about the potential influence of concomitant losses in muscle mass

Clinical trials (ten studies, 419 participants) using doses from 400 mg to 10 g over 21 days to 20 months show consistent reductions in fasting glucose, post-meal glucose, and HbA1c. In diabetic animal studies, gymnema increased proglucagon gene expression (a precursor for GLP-1) and insulin gene activity, suggesting it may help amplify endogenous GLP-1 production